logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer's Xarelto Approved In EU For Preventing Stroke In Patients With AF

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said Bayer HealthCare's oral anticoagulant Xarelto (rivaroxaban) has been approved by the European Commission for use in two new indications, making it the only new oral anticoagulant approved in three indications across all 27 EU member states.

Xarelto is approved for preventing stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, or AF, with one or more risk factors and for treatment of deep vein thrombosis, or DVT, and prevention of recurrent DVT and pulmonary embolism following an acute DVT in adults. It is also approved for prevention of Venous Thromboembolism, or VTE, in adult patients undergoing elective hip or knee replacement surgery.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Best Buy Co., Inc. reported lower profit in its first quarter on the absence of last year's CRT settlement proceeds. However, earnings per share topped market estimates significantly with higher comparable sales. Looking ahead, for the second quarter, the company projects higher comparable sales, and also lifted fiscal 2018 forecast for higher growth.In pre-market, shares were gaining 11.9 percent The Federal Communications Commission or FCC will not take any action against CBS Corp.'s "Late Show with Stephen Colbert" despite receiving thousands of complaints about the talk show comedian's controversial joke about President Donald Trump. The U.S. government filed a civil lawsuit on Tuesday against Fiat Chrysler Automobiles, accusing the automaker of installing software in more than 100,000 diesel vehicles to cheat emission controls. The lawsuit alleges that Fiat Chrysler equipped nearly 104,000 light duty diesel vehicles containing 3.0 liter EcoDiesel engines with software functions that were not disclosed to regulators.
comments powered by Disqus
Follow RTT